Common use of In Re Clause in Contracts

In Re. Yasmin and YAZ (Drospirenone) Marketing, Sales Practices and Products Liability Litigation, MDL No. 2100 (the “MDL”), a federal multi-district litigation venued in the United States District Court for the Southern District of Illinois (the “MDL Court”); (2) any other federal court proceedings pertaining to actions, disputes, and claims asserted against Defendants regarding the use of drospirenone- containing oral contraceptives manufactured by Bayer or manufactured or marketed by BarrTeva (collectively, “DCOCs”), either pending in that court or removed therefrom and awaiting transfer to the MDL (collectively, the “Other Federal Court Proceedings”), and (3) In re Yaz, Yasmin and Ocella Contraceptive Cases, Case No. JCCP 4608 (Superior Court of the State of California, County of Los Angeles) (the “California Coordinated Proceedings”), In RE: Yaz/Yasmin/Ocella Litigation, BER-L-3572-10 (Superior Court, Law Division, Bergen County) (the “New Jersey Coordinated Proceedings”), and In re: Yaz/Yasmin/Ocella/Gianvi Products Liability Litigation, September Term, 2009. No 1307 (Court of Common Pleas of Philadelphia County, Trial Division-Civil) (the “Philadelphia Court of Common Pleas Coordinated Proceeding”) pending in their respective courts (collectively, the “State Coordinating Courts”). The Gallbladder Resolution Program established pursuant to this Settlement Agreement also is open to Claimants in any and all other state court proceedings pertaining to actions, disputes, and claims asserted against Defendants regarding the use of DCOCs (together with the cases pending in the State Coordinating Courts, the “State Court Proceedings”).

In Re. Yasmin Xxxxxx and YAZ XXX (Drospirenone) Marketing, Sales Practices and Products Liability Litigation, MDL No. 2100 (the “MDL”), a federal multi-district litigation venued in the United States District Court for the Southern District of Illinois (the “MDL Court”); (2) any other federal court proceedings pertaining to actions, disputes, and claims asserted against Defendants regarding the use of drospirenone- containing oral contraceptives manufactured by Bayer or manufactured or marketed by BarrTeva (collectively, “DCOCs”), either pending in that court or removed therefrom and awaiting transfer to the MDL (collectively, the “Other Federal Court Proceedings”), and (3) In re Yaz, Yasmin Xxxxxx and Ocella Xxxxxx Contraceptive Cases, Case No. JCCP 4608 (Superior Court of the State of California, County of Los Angeles) (the “California Coordinated Proceedings”), In RE: Yaz/YasminXxxxxx/Ocella Litigation, BER-L-3572-10 (Superior Court, Law Division, Bergen County) (the “New Jersey Coordinated Proceedings”), and In re: Yaz/YasminXxxxxx/OcellaXxxxxx/Gianvi Products Liability Litigation, September Term, 2009. No 1307 (Court of Common Pleas of Philadelphia County, Trial Division-Civil) (the “Philadelphia Court of Common Pleas Coordinated Proceeding”) pending in their respective courts (collectively, the “State Coordinating Courts”). The Gallbladder Resolution Program established pursuant to this Settlement Agreement also is open to Claimants in any and all other state court proceedings pertaining to actions, disputes, and claims asserted against Defendants regarding the use of DCOCs (together with the cases pending in the State Coordinating Courts, the “State Court Proceedings”).